2018
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer
Basu B, Krebs M, Sundar R, Wilson R, Spicer J, Jones R, Brada M, Talbot D, Steele N, Garces A, Brugger W, Harrington E, Evans J, Hall E, Tovey H, de Oliveira F, Carreira S, Swales K, Ruddle R, Raynaud F, Purchase B, Dawes J, Parmar M, Turner A, Tunariu N, Banerjee S, de Bono J, Banerji U. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Annals Of Oncology 2018, 29: 1918-1925. PMID: 30016392, PMCID: PMC6158767, DOI: 10.1093/annonc/mdy245.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBenzamidesCarcinoma, Non-Small-Cell LungDrug Administration ScheduleFemaleHumansLung NeoplasmsMaleMaximum Tolerated DoseMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2Middle AgedMorpholinesOvarian NeoplasmsPaclitaxelPhosphorylationProtein Kinase InhibitorsPyrimidinesResponse Evaluation Criteria in Solid TumorsRibosomal Protein S6 KinasesConceptsHigh-grade serous ovarian cancerSquamous non-small-cell lung cancerNon-small-cell lung cancerWeekly paclitaxelOvarian cancerSchedule ALung cancerIntermittent scheduleRecommended phase II doseResponse rateDose-escalated armPhase II doseRECIST response rateDose-limiting toxicityProgression-free survivalAdvanced solid tumorsPhase I trialSerous ovarian cancerResistance to chemotherapyP-S6K levelsConsecutive daysII doseDose escalationExpansion cohortI trial
2017
Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer
Dolly S, Collins D, Sundar R, Popat S, Yap T. Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs 2017, 77: 813-827. PMID: 28378229, DOI: 10.1007/s40265-017-0732-2.Peer-Reviewed Original ResearchConceptsAnaplastic lymphoma kinaseEpidermal growth factor receptorDevelopment of molecular-targeted agentsAdvent of immune checkpoint inhibitorsNon-small-cell lung cancerPredictive biomarkers of responseEmergence of acquired resistanceTreatment approachesAdvanced NSCLC patientsImmune checkpoint inhibitorsProgression-free survivalMolecular targeted agentsBiomarkers of responseNon-small-cellTreatment of patientsCancer-related mortalityGrowth factor receptorMutation-specific inhibitorsAnti-tumor agentsCheckpoint inhibitorsNSCLC patientsGene aberrationsDownstream signaling blockadePredictive biomarkersMolecular subtypes